Public Sector Pension Investment Board Has $2.88 Million Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Public Sector Pension Investment Board lessened its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 10.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 258,558 shares of the biopharmaceutical company’s stock after selling 29,400 shares during the period. Public Sector Pension Investment Board owned 0.20% of Dynavax Technologies worth $2,880,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Bank of Montreal Can lifted its holdings in Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after buying an additional 82,449 shares during the period. Intech Investment Management LLC acquired a new position in shares of Dynavax Technologies in the third quarter worth approximately $416,000. Quest Partners LLC bought a new stake in Dynavax Technologies in the third quarter valued at approximately $237,000. Mizuho Markets Americas LLC increased its position in Dynavax Technologies by 17.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock valued at $15,369,000 after purchasing an additional 204,475 shares during the period. Finally, Aigen Investment Management LP bought a new position in Dynavax Technologies during the 3rd quarter worth approximately $228,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

Dynavax Technologies stock opened at $12.79 on Wednesday. The stock’s 50 day moving average price is $11.73 and its two-hundred day moving average price is $11.41. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of 98.39 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DVAX. The Goldman Sachs Group decreased their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.